Inozyme Pharma (NASDAQ:INZY) Stock Rating Upgraded by Zacks Investment Research
Inozyme Pharma (NASDAQ:INZY – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Tuesday, Zacks.com reports. The brokerage presently has a $4.50 price target on the stock. Zacks Investment Research‘s price objective would indicate a potential upside of 13.35% from the company’s previous close.
According to Zacks, “Inozyme Pharma Inc. is a biopharmaceutical company. It engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue and skeleton diseases. The company’s product candidate consist INZ-701, which is in clinical stage. Inozyme Pharma Inc. is based in Boston, Massachusetts. “
A number of other research firms have also weighed in on INZY. Wedbush lowered their price objective on shares of Inozyme Pharma from $25.00 to $23.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 10th. HC Wainwright started coverage on shares of Inozyme Pharma in a report on Monday, February 7th. They issued a “buy” rating and a $33.00 target price on the stock. Jefferies Financial Group initiated coverage on shares of Inozyme Pharma in a report on Thursday, May 26th. They set a “hold” rating and a $5.00 price target for the company. Finally, Needham & Company LLC initiated coverage on Inozyme Pharma in a report on Thursday, April 14th. They issued a “buy” rating and a $23.00 price objective on the stock. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $17.70.
Shares of INZY stock opened at $3.97 on Tuesday. The stock has a market capitalization of $159.19 million, a PE ratio of -1.51 and a beta of 1.12. Inozyme Pharma has a 52-week low of $3.54 and a 52-week high of $19.58. The stock’s 50-day moving average price is $4.25 and its 200 day moving average price is $5.81.
Inozyme Pharma (NASDAQ:INZY – Get Rating) last announced its earnings results on Tuesday, May 10th. The company reported ($0.71) earnings per share for the quarter, beating the consensus estimate of ($0.82) by $0.11. As a group, equities research analysts predict that Inozyme Pharma will post -2.28 earnings per share for the current year.
In other news, major shareholder Longitude Capital Partners Iii acquired 1,355,000 shares of the company’s stock in a transaction that occurred on Tuesday, April 19th. The stock was purchased at an average cost of $3.69 per share, with a total value of $4,999,950.00. Following the purchase, the insider now directly owns 4,174,379 shares of the company’s stock, valued at approximately $15,403,458.51. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Axel Bolte acquired 67,750 shares of Inozyme Pharma stock in a transaction that occurred on Tuesday, April 19th. The shares were purchased at an average cost of $3.69 per share, with a total value of $249,997.50. Following the completion of the acquisition, the chief executive officer now owns 258,575 shares of the company’s stock, valued at approximately $954,141.75. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 2,519,850 shares of company stock worth $9,298,247. Corporate insiders own 9.72% of the company’s stock.
Several hedge funds have recently made changes to their positions in the company. PDT Partners LLC acquired a new stake in shares of Inozyme Pharma in the first quarter valued at approximately $42,000. Renaissance Technologies LLC acquired a new stake in Inozyme Pharma during the 1st quarter valued at $49,000. Citigroup Inc. grew its holdings in Inozyme Pharma by 241.6% during the 1st quarter. Citigroup Inc. now owns 12,517 shares of the company’s stock valued at $51,000 after buying an additional 8,853 shares during the last quarter. Wells Fargo & Company MN increased its position in Inozyme Pharma by 16,531.3% during the fourth quarter. Wells Fargo & Company MN now owns 7,983 shares of the company’s stock worth $54,000 after buying an additional 7,935 shares in the last quarter. Finally, Bank of America Corp DE raised its holdings in shares of Inozyme Pharma by 4,030.0% in the fourth quarter. Bank of America Corp DE now owns 11,853 shares of the company’s stock worth $81,000 after acquiring an additional 11,566 shares during the last quarter.
About Inozyme Pharma (Get Rating)
Inozyme Pharma, Inc, a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company’s lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inozyme Pharma Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Inozyme Pharma and related companies with MarketBeat.com’s FREE daily email newsletter.